Synektik S.A. stock (PLSYNEK00016): medical technology group secures oncology order and expands imaging portfolio

Polish medtech group Synektik S.A. has reported new contract wins in oncology and continued demand for diagnostic imaging systems, keeping the spotlight on its nuclear medicine and robotics business in Central Europe.

Polish medical technology company Synektik S.A. recently highlighted new orders in oncology and diagnostic imaging, underlining ongoing demand for its radiopharmaceuticals and advanced imaging solutions in Central Europe, according to an investor update published in early 2025 on the company’s website (Synektik investor relations as of 02/05/2025).

In addition, the group pointed to a growing installed base in imaging diagnostics and radiotherapy planning, supported by its cooperation with international technology partners, as stated in a corporate presentation released in 2024 on its investor relations pages (Synektik investor materials as of 09/20/2024).

As of: 05/22/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Synektik
• Sector/industry: Medical technology, diagnostic imaging, nuclear medicine
• Headquarters/country: Poland
• Core markets: Central and Eastern Europe, with European Union exposure
• Key revenue drivers: Diagnostic imaging systems, radiopharmaceuticals, oncology solutions
• Home exchange/listing venue: Warsaw Stock Exchange (ticker: SNT)
• Trading currency: Polish zloty (PLN)

Synektik S.A.: core business model

Synektik S.A. focuses on medical technology solutions for hospitals and diagnostic centers, with a particular emphasis on imaging and nuclear medicine. The company supplies equipment such as PET/CT scanners, SPECT systems and related infrastructure, according to its corporate profile on the official website (Synektik corporate profile as of 03/15/2025). These systems support cancer diagnostics, cardiology and neurology applications.

Alongside equipment distribution and integration, Synektik manufactures and supplies radiopharmaceuticals used in positron emission tomography. These products are typically produced in specialized radiopharmacies and delivered on a just?in?time basis due to their short half?life, as described in an overview of the group’s nuclear medicine operations released on its website in 2024 (Synektik nuclear medicine overview as of 07/10/2024). The combination of equipment and consumables can provide recurring revenue streams.

The company also engages in integration projects, helping hospitals design and deploy imaging departments and radiotherapy planning systems. These projects may include installation, calibration, software integration and training, creating multi?year relationships with healthcare providers. According to Synektik, such projects are often supported by European structural funds and national health programs in Poland and neighboring EU markets (Synektik investor information as of 11/05/2024).

Main revenue and product drivers for Synektik S.A.

Diagnostic imaging solutions represent a central pillar of Synektik’s revenue. The company acts as a systems integrator and distributor for advanced modalities, offering turnkey delivery and long?term service contracts. In its financial communications for the 2023/24 reporting period, Synektik noted that demand for oncology imaging in Poland continues to grow, driven by demographic trends and expanding screening programs (Synektik financial report as of 01/31/2025).

Radiopharmaceuticals form another key revenue stream. The company operates production facilities that serve imaging centers in Poland and potentially other EU markets, supplying tracers used in PET examinations. In a business update published in mid?2024, management emphasized that recurring demand for these tracers helps stabilize revenue between large equipment projects (Synektik business update as of 06/18/2024). Pricing and volume depend on procedure numbers and reimbursement policies.

Synektik also reports activity in advanced therapy planning and robotics?assisted procedures, working with global technology partners to introduce novel solutions into Central European hospitals. These offerings may include software platforms for radiotherapy planning and minimally invasive surgery support, according to a partner presentation referenced on the company’s site in late 2024 (Synektik partners overview as of 10/22/2024). While such segments can be smaller today, they may influence future growth and margin structure.

Conclusion

Synektik S.A. positions itself as a specialized medtech and nuclear medicine provider focused on Central European healthcare systems. The combination of imaging equipment projects, radiopharmaceuticals and therapy?planning solutions creates a diversified revenue mix that is tied closely to oncology and diagnostic procedure volumes. For US?based investors, the stock offers exposure to healthcare infrastructure development within the European Union but also entails currency, regulatory and regional demand risks. Future performance will depend on the company’s ability to win new contracts, maintain utilization at its radiopharmacies and navigate public?sector investment cycles in its home markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.